Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mein-Woei Suen has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and correlates of early fatherhood among young Filipino men

    by Earl Francis Infante Mallari, Karl Peltzer, Mein-Woei Suen, Arbie Diane A. Flores, Joemer Calderon Maravilla

  • Open Access

    Reassessing the risk-modifying effects of novel antidiabetic agents on asthma–COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials

    by Bing-Yan Zeng, Chih-Wei Hsu, Chao-Ming Hung, Wei-Chieh Yang, Brendon Stubbs, Yen-Wen Chen, Wei-Te Lei, Jiann-Jy Chen, Tien-Yu Chen, Shih-Pin Hsu, et al.

  • Active Travel to School, Psychological Distress, Health Risk Behaviors, and Social-Environmental Factors Among Filipino Adolescents

    by Earl Francis Infante Mallari, Karl Peltzer, Lyndon Esconde Santos, Huyen-Trang Luu-Thi, Thanh-Thao Nguyen-Thi, Kristine Lin, Mein-Woei Suen

    Introduction : Active travel to school—walking or biking to school—is a valuable source of physical activity with benefits for physical and mental health. This study examined the association of active travel to school with psychological distress, health risk behaviors, and social-environmental factors among Filipino school-going adolescents. Methods : The current study analyzed data from the 2011, 2015, and 2019 Global School-based Health Survey. Results : Multivariable logistic regressions showed that those who engaged in frequent active travel to school were more likely to report loneliness and sedentary behavior (≥3 h). On the other hand, frequent active travel was associated with lower chances of having no close friends, being physically inactive, reporting infrequent physical activity, physical education attendance, drinking alcohol, using tobacco, marijuana, and drugs, and consuming fast-food and soft drinks. Conclusions : These findings suggest that frequent active travel to school is linked to more beneficial than detrimental outcomes. Policymakers are encouraged to strengthen infrastructure that supports safe walking and biking to school to maximize these health and social benefits for Filipino youth.


  • Open Access

    Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis

    by Chih-Sung Liang, Chih-Wei Hsu, Jiann-Jy Chen, Chao-Ming Hung, Bing-Yan Zeng, Wei-Chieh Yang, Mein-Woei Suen, Hung-Yu Wang, Andre F. Carvalho, Brendon Stubbs, et al.

    Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium–glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated protective effects against chronic kidney disease, their impact on acute kidney injury (AKI) remains unclear. AKI and chronic kidney disease share overlapping clinical features but differ in pathogenesis and risk profiles. Previous analyses often grouped diverse agents into single categories, potentially concealing medication-specific renal risks. Given the widespread assumption of renoprotection, particularly among newer agents, there is a need to evaluate the comparative AKI risk of GLP-1RAs and SGLT2is at the individual drug and dose level. We performed a Bayesian network meta-analysis (NMA) following Cochrane-recommended methodology for safety-focused assessments. A systematic literature search across eight databases identified 67 randomized controlled trials (RCTs), including 199,877 participants. Eligible trials reported AKI outcomes or sufficiently explicit acute renal injury-related events associated with GLP-1RA or SGLT2i interventions. The primary outcome was the incidence of AKI; all-cause dropout was analyzed as a general tolerability measure. Odds ratios (ORs) with 95% credible intervals (CrIs) were calculated, and surface under the cumulative ranking curves (SUCRA) were used to estimate relative safety rankings. Only high-dose tirzepatide (10–15 mg/week) was associated with a significantly increased risk of AKI compared to controls (absolute risk difference: 0.28%; number needed to harm: 357). In contrast, lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin were associated with reduced AKI risk. Risk rankings consistently identified high-dose tirzepatide as the most likely to induce AKI. Subgroup analyses excluding patients with baseline renal impairment yielded consistent results. High-dose tirzepatide may elevate AKI risk despite its metabolic benefits. Clinicians should assess renal vulnerability when prescribing GLP-1RAs or SGLT2is, particularly in patients with preserved kidney function. Further prospective trials are needed to clarify causal mechanisms and inform clinical decision-making.

  • Open Access

    Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials

    by Chao-Ming Hung, Chih-Wei Hsu, Bing-Syuan Zeng, Mein-Woei Suen, Jiann-Jy Chen, Bing-Yan Zeng, Andre F. Carvalho, Brendon Stubbs, Yen-Wen Chen, Tien-Yu Chen, et al.

    Whether the risk of gastric neoplasm is modified by newer glucose-lowering therapies—dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP1RAs), and sodium–glucose cotransporter 2 inhibitors (SGLT2is)—remains uncertain. Given their global uptake and long-term use in populations already predisposed to malignancy, decision-grade comparative safety evidence is needed. We conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) in adults without baseline gastric neoplasms. PubMed, Embase, Cochrane CENTRAL, Web of Science, ClinicalTrials.gov, ClinicalKey, ProQuest, and ScienceDirect were searched from inception to 10 January 2026, without language restrictions. The primary outcome was incident gastric neoplasms (benign or malignant). Random-effects frequentist NMA estimated risk ratios (RRs) with 95% confidence intervals (CIs); Bayesian NMA served as sensitivity analysis. Certainty of evidence was assessed using GRADE adapted for NMA (PROSPERO CRD420261282728). Fifty-two RCTs (171,165 participants; mean age 63.6 years; 36.9% women; mean follow-up 141.8 weeks) were included. At the class level, GLP1RAs were associated with lower gastric neoplasm risk versus controls (RR = 0.51, 95% CI = 0.28–0.92), whereas DPP4is were associated with higher risk (RR = 1.77, 95% CI = 1.09–2.85). These signals persisted in prespecified subgroup analyses among participants with diabetes mellitus, in trials with duration ≥52 weeks (GLP1RA: RR = 0.52, 95% CI = 0.28–0.95; DPP4i: RR = 2.05, 95% CI = 1.19–3.55), and in older populations (age ≥60 years; DPP4i: RR = 2.08, 95% CI = 1.15–3.77). No class showed a significant association in younger participants (<60 years) or shorter trials (<52 weeks). Across available RCT evidence, GLP1RA prescription generally had a relatively lower gastric neoplasm risk than controls. In contrast, among patients with diabetes mellitus receiving longer-term therapy, GLP1RAs may be the preferable option from the perspective of gastric neoplasm risk, while DPP4is warrant heightened vigilance and mechanistic clarification. These findings support improved neoplasms ascertainment in future trials rather than immediate prescribing changes.

  • Open Access

    Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials

    by Jiann-Jy Chen, Chih-Wei Hsu, Chao-Ming Hung, Mein-Woei Suen, Hung-Yu Wang, Wei-Chieh Yang, Brendon Stubbs, Yen-Wen Chen, Tien-Yu Chen, Wei-Te Lei, et al.

    Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors have reshaped pharmacological management of type 2 diabetes, but emerging safety signals suggest a possible association with intestinal obstruction. Because many candidates for these agents already harbor risk factors for ileus and bowel obstruction, clarifying agent- and dose-specific gastrointestinal safety is clinically important. We aimed to re-evaluate the risk of intestinal obstruction across individual GLP-1 receptor agonists and SGLT2 inhibitors, with particular attention to dose stratification. We systematically searched eight databases through 21 January 2025 to identify randomized controlled trials (RCTs) comparing GLP-1 receptor agonists or SGLT2 inhibitors with placebo or active comparators in adults. The primary outcome was incident intestinal obstruction (small or large bowel). A frequentist random-effects network meta-analysis estimated odds ratios (ORs) with 95% confidence intervals (CIs) across drugs and dose tiers; Bayesian models and surface under the cumulative ranking (SUCRA) metrics were used for sensitivity analyses and treatment ranking. Risk of bias and certainty of evidence were assessed with standard Cochrane and GRADE-adapted tools. Fifty RCTs (47 publications; 192,359 participants) met inclusion criteria. Overall, canagliflozin use was associated with a higher incidence of intestinal obstruction than control therapies (OR 2.56, 95% CI 1.01–6.49), corresponding to an absolute risk difference of 0.15% and a number needed to harm of 658. High-dose canagliflozin (300 mg/day) showed the clearest signal (OR 3.42, 95% CI 1.08–10.76). In contrast, liraglutide was associated with a lower risk of intestinal obstruction (OR 0.44, 95% CI 0.24–0.81), with an absolute risk reduction of 0.34% and a number needed to treat of 295. No other GLP-1 receptor agonist or SGLT2 inhibitor demonstrated a statistically significant increase in obstruction risk. Frequentist and Bayesian analyses yielded concordant estimates and rankings. From a randomized-trial perspective, intestinal obstruction risk is not elevated for most GLP-1 receptor agonists and SGLT2 inhibitors. A dose-dependent safety signal was observed only for high-dose canagliflozin, whereas liraglutide may confer a protective effect. These findings refine gastrointestinal safety profiles for modern antidiabetic agents and may inform perioperative bowel management, drug selection, and dose optimization in patients at risk for ileus or adhesive obstruction.


  • Open Access

    Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis

    by Pao-Yen Lin, Bing-Yan Zeng, Chih-Wei Hsu, Mein-Woei Suen, Chao-Ming Hung, Brendon Stubbs, Yen-Wen Chen, Tien-Yu Chen, Wei-Te Lei, Jiann-Jy Chen, et al.

    Background: Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors have gained attention for their broad therapeutic effects, their influence on hematologic malignancy remains underexplored. Given the high mortality associated with hematologic cancers, clarifying the impact of these agents on such malignancies is essential. Objectives: This pilot network meta-analysis (NMA) aimed to assess the comparative risk of hematologic malignancies—including lymphoma, leukemia, and myeloma—associated with various GLP-1 receptor agonists and SGLT2 inhibitors. Methods: Following Cochrane-recommended confirmatory methods, we systematically searched multiple databases for randomized controlled trials (RCTs) published through 4 December 2024. The primary outcome was the incidence of overall hematologic malignancies. A frequentist random-effects NMA via the netmeta package was conducted, with additional validation through Bayesian NMA for solely sensitivity analyses. Results: Fifty-five RCTs (n = 200,606) were analyzed. Dulaglutide showed a significantly higher risk of overall hematologic malignancy [odds ratio (OR) = 2.18, 95% confidence interval (95%CI) = 1.14–4.19). In contrast, tirzepatide was linked to a significantly reduced risk (OR = 0.14, 95%CI = 0.03–0.60), especially for lymphoma. No statistically significant associations were identified for SGLT2 inhibitors (i.e., 95%CI across 1.0). Conclusions: Our preliminary findings reveal distinct and agent-specific effects of GLP-1 receptor agonists on hematologic malignancy risk. While dulaglutide may elevate the risk, tirzepatide appears protective, particularly against lymphoma. These results call for further long-term mechanistic studies to clarify causality and underlying pathways.


  • Open Access

    Risk and Protective Factors of Indonesian Women Migrant Workers in Malaysia

    by Myrtati Dyah Artaria, Ike Herdiana, Sayf Muhammad Alaydrus, Mein-Woei Suen

    This study was conducted to identify the risk and protective factors of Indonesian women migrant workers in Malaysia. The risk factors are variables that contribute to one’s psychological stresses, while the protective factors are variables that contribute to one’s mental stability. The “risk and protective” concept is fluid, relative, and often overlaps according to the individuals and situations. Data for the qualitative study was gathered using semi-structured interviews with five Indonesian women migrant workers in Malaysia. The risk factors include family poverty, poor communication, employee conflicts, and workplace hostility. Expertise and professional experience, as well as family and state support, are identified as protective factors. A combination of both protective and risk factors was also discovered, namely the recruitment and departure processes, educational background, work knowledge, working hours, healthcare access, and coping mechanisms. Understanding these aspects allows individuals to take precautions against problems upon arrival in their destination states. An insight provided by this study might inspire the stakeholders to increase international migrant workers’ protection framework and further ensure their human rights.


  • Open Access

    Accessible information and inclusive education for students with disabilities in Universitas Airlangga, Indonesia

    by Myrtati Dyah Artaria, Mein-Woei Suen, Sayf Muhammad Alaydrus

    Background of the study: Education is a basic human right for all, including persons with disabilities. The right to information for students with disabilities is guaranteed by the national law of the Republic of Indonesia. However, students with disabilities still face discrimination and marginalization on campus that might impede their academic achievement and subjective well-being. Purpose: This study aims to explore information experiences of students with disabilities in Universitas Airlangga, which includes information on university policies, research opportunities, student organizations, and career opportunities. Method: This study employed a mixed-methods approach by conducting in-depth interviews with students with disabilities (n = 5), surveys with non-disabled students (n = 106), and focus group discussions with faculty representatives (n = 10). Findings: This study found that inaccessible information continues to be a problem for students with disabilities. However, some of their non-disabled peers, professors, and staff members have been relatively helpful in navigating their respective campus lives. The commitment to inclusive education is shown by the university and faculties within, but effective and sustainable action is required to tackle these issues. Conclusion: The authors recommend that the university utilize already-existing organizations to conduct workshops and promote inclusive learning on campus.